Abstract

Since 1950, 25 anti-obesity drugs have been withdrawn from use across the world, largely as a result of adverse effects.¹ For several years, orlistat has been the only drug licensed in the UK for weight management.² In January 2017, a new presentation of the glucagon-like peptide-1 (GLP-1) analogue liraglutide (▾Saxenda - Novo Nordisk) was launched in the UK as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults. Here, we review the evidence for its efficacy and safety and consider its place in managing people who are overweight or obese.